Health Insurance Association Consortium and Celltrion to Co-Host Online Seminar for IBD Patients
Key facts
- Health Insurance Association Consortium and Celltrion to Co-Host Online Seminar for IBD Patients
- The 'Consortium for Biosimilar Promotion Model Projects' by health insurance associations and Celltrion Healthcare Japan will co-host an online seminar for IBD patients across Japan on June 28, 2026. Doctors and pharmacists will provide insights on the latest treatments and medications.
- Source: PR Times
- Date: May 22, 2026
Direct answer
The 'Consortium for Biosimilar Promotion Model Projects' by health insurance associations and Celltrion Healthcare Japan will co-host an online seminar for IBD patients across Japan on June 28, 2026. Doctors and pharmacists will provide insights on the latest treatments and medications.
- Citation
- Health Insurance Association Consortium and Celltrion to Co-Host Online Seminar for IBD Patients (May 22, 2026), PR Times
- Source
- PR Times
- Date
- May 22, 2026
The 'Consortium for Biosimilar Promotion Model Projects' by health insurance associations and Celltrion Healthcare Japan will co-host an online seminar for IBD patients across Japan on June 28, 2026. Doctors and pharmacists will provide insights on the latest treatments and medications.
📋 Article Processing Timeline
- 📰 Published: May 22, 2026 at 19:00
- 🔍 Collected: May 22, 2026 at 10:31
- 🤖 AI Analyzed: May 22, 2026 at 10:35 (3 min after Collected)
This consortium is managed by White Healthcare Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Representative Director: Junichiro Ishizuka), which specializes in healthcare cost optimization consulting. This initiative has been adopted as a joint project under the Ministry of Health, Labour and Welfare's 'Subsidy for Smooth Operation of Elderly Healthcare in FY2025,' and now includes 11 participating health insurance associations with a total of approximately 1.26 million members (as of the end of FY2025).
This seminar is a new initiative where health insurance associations and a pharmaceutical company partner to provide accurate treatment information to IBD patients. Doctors and pharmacists will explain basic knowledge of medications, treatment options, and out-of-pocket costs to support patients in undergoing treatment with confidence.
Seminar Overview
Date/Time: June 28, 2026 (Sun) 14:00–15:30
Format: Online
Target: IBD patients across Japan
Content:
'Evolving IBD Treatment! What are Molecular Targeted Drugs and Biologics?' by Dr. Takuya Araki (Associate Professor, Department of Clinical Pharmacology, Gunma University Graduate School of Medicine)
'Progress and Future of IBD Treatment: Daily life changes with the latest drugs and treatment options' by Dr. Keiji Ozeki (Director of Gastroenterology, JCHO Chukyo Hospital)
Secretariat: White Healthcare Co., Ltd.
FAQ
What is the purpose of the online seminar?
The purpose is for health insurance cooperatives and pharmaceutical companies to collaborate and provide accurate information to IBD patients about treatment (basic knowledge of medications, treatment options, out-of-pocket costs, etc.) to support them in facing their treatment with peace of mind.
Who is the target audience for the seminar?
The target audience is IBD patients nationwide.
What is the Health Insurance Cooperative Bio-similar Promotion Model Project Consortium?
It is a framework where multiple health insurance cooperatives share knowledge and collaborate to promote awareness of biosimilars. It was established in 2024, with White Healthcare Co., Ltd. serving as the secretariat.
What is the status of this initiative?
It is recognized as a joint project under the 'Fiscal Year 2025 Subsidy for Smooth Operation of Elderly Medical Care' by the Ministry of Health, Labour and Welfare.
What kind of company is Celltrion Healthcare Japan?
It is the Japanese subsidiary of Celltrion, South Korea's largest biopharmaceutical manufacturing and exporting company. It develops and sells biosimilars and antibody biopharmaceuticals in the fields of autoimmune diseases and cancer.